Jasper Therapeutics is trading at $0.66, down 5.29% after-hours on September 1, 2026, amid broad risk aversion as U.S.-Iran tensions lifted oil prices and pressured biotechnology shares.
- The stock declined 1.94% during the regular session; the Nasdaq fell 1.15% and XBI declined 4.24%.
- No new company-specific announcement was identified; the latest investor-relations update was the August 14, 2026, second-quarter report.